Loading...

Osprey Medical

ASX:OSP
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
OSP
ASX
A$65M
Market Cap
  1. Home
  2. AU
  3. Healthcare
Company description

Osprey Medical, Inc., a commercial stage company, focuses on protecting patients from the harmful effects of X-ray dye used during commonly performed angiographic imaging procedures in the United States and internationally. The last earnings update was 31 days ago. More info.


Add to Portfolio Compare Print
  • Osprey Medical has significant price volatility in the past 3 months.
OSP Share Price and Events
7 Day Returns
-6.3%
ASX:OSP
0.7%
AU Medical Equipment
1.7%
AU Market
1 Year Returns
-14.3%
ASX:OSP
-1%
AU Medical Equipment
5.9%
AU Market
OSP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Osprey Medical (OSP) -6.3% 30.4% 15.4% -14.3% -42.3% -70%
AU Medical Equipment 0.7% 3.1% 0.1% -1% 44.1% 106.9%
AU Market 1.7% 4% 8.6% 5.9% 21.4% 7.4%
1 Year Return vs Industry and Market
  • OSP underperformed the Medical Equipment industry which returned -1% over the past year.
  • OSP underperformed the Market in Australia which returned 5.9% over the past year.
Price Volatility
OSP
Industry
5yr Volatility vs Market

OSP Value

 Is Osprey Medical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Osprey Medical. This is due to cash flow or dividend data being unavailable. The share price is A$0.15.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Osprey Medical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Osprey Medical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:OSP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.05
ASX:OSP Share Price ** ASX (2019-04-24) in AUD A$0.15
ASX:OSP Share Price converted to USD reporting currency Exchange rate (AUD/ USD) 0.702 $0.11
Australia Medical Equipment Industry PE Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 34.76x
Australia Market PE Ratio Median Figure of 543 Publicly-Listed Companies 16.28x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Osprey Medical.

ASX:OSP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:OSP Share Price ÷ EPS (both in USD)

= 0.11 ÷ -0.05

-2.13x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Osprey Medical is loss making, we can't compare its value to the AU Medical Equipment industry average.
  • Osprey Medical is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Osprey Medical's expected growth come at a high price?
Raw Data
ASX:OSP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.13x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
40.6%per year
Oceania Medical Equipment Industry PEG Ratio Median Figure of 5 Publicly-Listed Medical Equipment Companies 2.67x
Australia Market PEG Ratio Median Figure of 359 Publicly-Listed Companies 1.36x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Osprey Medical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Osprey Medical's assets?
Raw Data
ASX:OSP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.06
ASX:OSP Share Price * ASX (2019-04-24) in AUD A$0.15
ASX:OSP Share Price converted to USD reporting currency Exchange rate (AUD/ USD) 0.702 $0.11
Australia Medical Equipment Industry PB Ratio Median Figure of 30 Publicly-Listed Medical Equipment Companies 2.78x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.66x
ASX:OSP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:OSP Share Price ÷ Book Value per Share (both in USD)

= 0.11 ÷ 0.06

1.78x

* Primary Listing of Osprey Medical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Osprey Medical is good value based on assets compared to the AU Medical Equipment industry average.
X
Value checks
We assess Osprey Medical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Osprey Medical has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

OSP Future Performance

 How is Osprey Medical expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
40.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Osprey Medical expected to grow at an attractive rate?
  • Unable to compare Osprey Medical's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Osprey Medical's earnings growth to the Australia market average as it is expected to be loss making during the next 1-3 years.
  • Osprey Medical's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:OSP Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:OSP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 40.6%
ASX:OSP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 40.9%
Australia Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 13.2%
Australia Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.4%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.8%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:OSP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:OSP Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 40 1
2022-12-31 27 1
2021-12-31 16 1
2020-12-31 12 -8 -7 2
2019-12-31 6 -13 -13 2
ASX:OSP Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 3 -17 -18
2018-09-30 2 -16 -17
2018-06-30 2 -16 -16
2018-03-31 2 -15 -15
2017-12-31 2 -14 -14
2017-09-30 1 -13 -13
2017-06-30 1 -11 -12
2017-03-31 1 -11 -12
2016-12-31 1 -11 -12
2016-09-30 0 -11 -12
2016-06-30 0 -11 -12
2016-03-31 0 -11 -12

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Osprey Medical is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Osprey Medical's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:OSP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Osprey Medical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:OSP Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 -0.02 -0.02 -0.02 1.00
2019-12-31 -0.03 -0.03 -0.03 1.00
ASX:OSP Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.05
2018-09-30 -0.05
2018-06-30 -0.05
2018-03-31 -0.05
2017-12-31 -0.05
2017-09-30 -0.05
2017-06-30 -0.05
2017-03-31 -0.06
2016-12-31 -0.06
2016-09-30 -0.05
2016-06-30 -0.08
2016-03-31 -0.08

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Osprey Medical will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Osprey Medical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Osprey Medical has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

OSP Past Performance

  How has Osprey Medical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Osprey Medical's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Osprey Medical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Osprey Medical's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Osprey Medical's 1-year growth to the AU Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Osprey Medical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Osprey Medical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:OSP Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 2.51 -17.52 15.35 3.64
2018-09-30 2.31 -16.96 14.44 3.74
2018-06-30 2.11 -16.40 13.53 3.85
2018-03-31 1.87 -15.37 12.49 3.54
2017-12-31 1.63 -14.34 11.45 3.23
2017-09-30 1.35 -13.33 10.32 3.25
2017-06-30 1.08 -12.32 9.19 3.26
2017-03-31 0.83 -12.03 8.66 3.37
2016-12-31 0.59 -11.74 8.13 3.47
2016-09-30 0.46 -11.85 8.28 3.38
2016-06-30 0.33 -11.96 8.43 3.30
2016-03-31 0.25 -12.06 8.77 3.11
2015-12-31 0.17 -12.16 9.11 2.92
2015-09-30 0.11 -11.73 8.71 2.80
2015-06-30 0.06 -11.29 8.30 2.68
2015-03-31 0.03 -10.51 7.42 2.85
2014-12-31 0.01 -9.72 6.54 3.01
2014-09-30 0.00 -9.25 5.97 3.21
2014-06-30 -8.77 5.41 3.40
2014-03-31 -8.69 5.67 3.06
2013-12-31 -8.61 5.93 2.72
2013-09-30 -8.12 5.84 2.31
2013-06-30 -7.63 5.75 1.90
2013-03-31 -6.87 4.74 1.83
2012-12-31 -6.10 3.73 1.77
2012-09-30 -6.08 3.64 1.57
2012-06-30 -6.05 3.56 1.38

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Osprey Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Osprey Medical has efficiently used its assets last year compared to the AU Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Osprey Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Osprey Medical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Osprey Medical has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

OSP Health

 How is Osprey Medical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Osprey Medical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Osprey Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Osprey Medical's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Osprey Medical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Osprey Medical has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Osprey Medical Company Filings, last reported 3 months ago.

ASX:OSP Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 25.53 0.00 25.25
2018-09-30 25.53 0.00 25.25
2018-06-30 23.83 0.00 23.33
2018-03-31 23.83 0.00 23.33
2017-12-31 32.36 0.00 32.13
2017-09-30 32.36 0.00 32.13
2017-06-30 15.31 0.00 15.05
2017-03-31 15.31 0.00 15.05
2016-12-31 21.64 0.00 21.85
2016-09-30 21.64 0.00 21.85
2016-06-30 5.96 0.00 5.81
2016-03-31 5.96 0.00 5.81
2015-12-31 11.64 0.00 11.78
2015-09-30 11.64 0.00 11.78
2015-06-30 17.14 0.00 17.08
2015-03-31 17.14 0.00 17.08
2014-12-31 11.11 0.00 11.32
2014-09-30 11.11 0.00 11.32
2014-06-30 15.58 0.00 15.12
2014-03-31 15.58 0.00 15.12
2013-12-31 20.06 0.00 16.19
2013-09-30 20.06 0.00 16.19
2013-06-30 10.95 0.00 10.97
2013-03-31 10.95 0.00 10.97
2012-12-31 15.16 0.00 15.16
2012-09-30 15.16 0.00 15.16
2012-06-30 18.16 0.00 18.24
  • Osprey Medical has no debt.
  • Osprey Medical has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Osprey Medical has sufficient cash runway for 1.5 years based on current free cash flow.
  • Osprey Medical has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 16.2% each year.
X
Financial health checks
We assess Osprey Medical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Osprey Medical has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

OSP Dividends

 What is Osprey Medical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Osprey Medical dividends.
If you bought A$2,000 of Osprey Medical shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Osprey Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Osprey Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:OSP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Oceania Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1.7%
Australia Market Average Dividend Yield Market Cap Weighted Average of 417 Stocks 4.2%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.5%
Australia Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:OSP Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Osprey Medical has not reported any payouts.
  • Unable to verify if Osprey Medical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Osprey Medical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Osprey Medical has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Osprey Medical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Osprey Medical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Osprey Medical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

OSP Management

 What is the CEO of Osprey Medical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mike McCormick
AGE 56
TENURE AS CEO 9.1 years
CEO Bio

Mr. Michael McCormick, also known as Mike has been the President and Chief Executive Officer of Osprey Medical Inc. since March 2010. Mr. McCormick has more than 20 years of experience in the medical device industry and president level experience. Mr. McCormick served as Chief Executive Officer and President of Anulex Technologies, Inc. until December 2008. He joined Anulex Technologies, Inc in December 2003. Mr. McCormick served as President for United States Operations of Spine-Tech Division, a division of Centerpulse Ltd. since August 2002. He served as President of Centerpulse Spine-Tech. He joined Centerpulse's Spine-Tech Division in 2000, as Vice President for Sales and later served as its Executive Vice President and General Manager of that division. He held various management positions with Boston Scientific/Scimed from 1990 to 2000, including Director of Sales and with Baxter Healthcare from 1986 to 1990. Mr. McCormick serves as Chairman of The Board at OrthoCor Medical, Inc. Mr. McCormick serves as member of the Board of Directors of Formae, Inc. He has been an Executive Director of Osprey Medical Inc. since March 2010. Mr. McCormick served as a Director of Anulex Technologies, Inc. until December, 2008. Mr. McCormick holds a Bachelors Degree in Business Administration from the University of Texas in Austin.

CEO Compensation
  • Insufficient data for Mike to compare compensation growth.
  • Insufficient data for Mike to establish whether their remuneration is reasonable compared to companies of similar size in Australia.
Management Team Tenure

Average tenure and age of the Osprey Medical management team in years:

6.8
Average Tenure
53.5
Average Age
  • The average tenure for the Osprey Medical management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Mike McCormick

TITLE
President
AGE
56
TENURE
9.1 yrs

J. Shapland

TITLE
Co-Founder

Nancy Ness

TITLE
VP of Finance & CFO
TENURE
8.9 yrs

Vic Fabano

TITLE
Vice President of Operations & IT
AGE
56
TENURE
6.8 yrs

Melanie Hess

TITLE
Vice President of Regulatory Affairs
TENURE
1.3 yrs

Doug Schoenberg

TITLE
Vice President of Marketing
AGE
48

Jim Surek

TITLE
VIce President of Sales
AGE
51
TENURE
0.1 yrs

Brendan Case

TITLE
Secretary
Board of Directors Tenure

Average tenure and age of the Osprey Medical board of directors in years:

7.9
Average Tenure
57.5
Average Age
  • The tenure for the Osprey Medical board of directors is about average.
Board of Directors

John Erb

TITLE
Non-Executive Chairman
AGE
69

Mike McCormick

TITLE
President
AGE
56
TENURE
9.1 yrs

Neville Mitchell

TITLE
Non-Executive Director
AGE
59
TENURE
6.8 yrs

Andy Jane

TITLE
Non-Executive Director
AGE
56
TENURE
6.4 yrs

David Kaye

TITLE
Member of Medical Advisory Board

Chris Nave

TITLE
Non-Executive Director
AGE
43
TENURE
13.5 yrs

Gregg Stone

TITLE
Member of Medical Advisory Board
AGE
61

Steve Bailey

TITLE
Member of Medical Advisory Board

David Lee

TITLE
Member of Medical Advisory Board

James Tumlin

TITLE
Member of Medical Advisory Board
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Osprey Medical insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
07. Mar 19 Buy Neville Mitchell Individual 04. Mar 19 04. Mar 19 185,809 A$0.11 A$20,362
14. Dec 18 Buy AustralianSuper Pty Ltd Company 10. Dec 18 10. Dec 18 9,318,749 A$0.16 A$1,491,005
02. Dec 18 Buy Neville Mitchell Individual 30. Nov 18 30. Nov 18 135,700 A$0.16 A$21,034
13. Nov 18 Sell Kinetic Investment Partners Limited Company 09. Sep 16 06. Nov 18 -713,123 A$0.39 A$-277,622
13. Nov 18 Buy Kinetic Investment Partners Limited Company 09. Sep 16 06. Nov 18 1,298,067 A$0.26 A$341,964
25. Sep 18 Sell JCP Investment Partners Limited Company 25. Oct 17 20. Sep 18 -1,282,743 A$0.43 A$-500,468
25. Sep 18 Buy JCP Investment Partners Limited Company 25. Oct 17 20. Sep 18 4,020,461 A$0.42 A$1,319,028
07. Jun 18 Buy Neville Mitchell Individual 04. Jun 18 06. Jun 18 250,000 A$0.15 A$37,478
15. May 18 Buy Neville Mitchell Individual 15. May 18 15. May 18 250,000 A$0.19 A$47,500
X
Management checks
We assess Osprey Medical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Osprey Medical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

OSP News

Simply Wall St News

If You Had Bought Osprey Medical (ASX:OSP) Stock Five Years Ago, You'd Be Sitting On A 78% Loss, Today

Osprey Medical isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … Shareholders of unprofitable companies usually expect strong revenue growth. … As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

Simply Wall St -

Does Osprey Medical, Inc. (ASX:OSP) Have A High Beta?

In finance, Beta is a measure of volatility. … Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility).

Simply Wall St -

Is Osprey Medical, Inc.'s (ASX:OSP) Balance Sheet Strong Enough To Weather A Storm?

However, the trade-off is OSP will have to follow strict debt obligations which will reduce its financial flexibility. … Is OSP growing fast enough to value financial flexibility over lower cost of capital … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital.

Simply Wall St -

What Kind Of Shareholders Own Osprey Medical Inc (ASX:OSP)?

The big shareholder groups in Osprey Medical Inc (ASX:OSP) have power over the company. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … Osprey Medical is not a large company by global standards.

Simply Wall St -

Osprey Medical Inc (ASX:OSP): Is Now The Time To Bet On Healthcare?

is a healthcare company operating in an industry, … the challenges facing the healthcare equipment in particular, are complex and interrelated … So, care delivery models that use a multi-pronged, collaborative, and technology-enabled approach are more likely to yield positive results.

Simply Wall St -

When Will Osprey Medical Inc (ASX:OSP) Breakeven?

Osprey Medical, Inc., a commercial stage company, focuses on protecting patients from the harmful effects of X-ray dye used during commonly performed angiographic imaging procedures in the United States and internationally. … The AU$49.23m market-cap company announced a latest loss of -AU$14.34m on 31 December 2017 for its most recent financial year result. … Check out our latest analysis for Osprey Medical

Simply Wall St -

Are Insiders Too Confident In Osprey Medical Inc (ASX:OSP)?

Osprey Medical's insiders have invested. … Generally, insiders buying more shares in their own firm sends a bullish signal … A two-decade research published in The MIT Press (1998) showed that stocks following insider buying outperformed the market by 4.5%.

Simply Wall St -

Top ASX Growth Stocks To Buy

Companies such as Osprey Medical and Qantm Intellectual Property have a significantly positive future outlook on the basis of their profitability and returns. … ASX:OSP Future Profit Feb 2nd 18 Qantm Intellectual Property Limited (ASX:QIP) QANTM Intellectual Property Limited providing IP services for start-up technology businesses, multinationals, public research institutions, and universities in Australia and internationally. … ASX:AVB Future Profit Feb 2nd 18 For more financially robust companies with high growth potential to enhance your portfolio, use our free platform to explore our interactive list of these stocks.

Simply Wall St -

December Growth Stock Opportunities

OSP is expected to deliver an extremely high earnings growth over the next couple of years of 75.32%, bolstered by a significant revenue which is expected to more than double. … The company currently has a market cap of AUD A$86.47M, putting it in the small-cap group ANR is expected to deliver an extremely high earnings growth over the next couple of years of 64.81%, bolstered by a significant revenue which is expected to more than double. … ASX:DCN Future Profit Dec 29th 17 For more financially robust companies with high growth potential to enhance your portfolio, use our free platform to explore our interactive list of these stocks.

Simply Wall St -

October Growth Stock Opportunities

OSP is expected to deliver an extremely high earnings growth over the next couple of years of 75.32%, bolstered by a significant revenue which is expected to more than double. … Though some cost-cutting activities may artificially inflate margins, it appears that this isn’t solely the case here, as profit growth is also coupled with high top-line expansion. … Driven by the exceptional 95.06% sales growth over the next few years, PAC is expected to deliver an excellent earnings growth of 81.58%.

Simply Wall St -

OSP Company Info

Description

Osprey Medical, Inc., a commercial stage company, focuses on protecting patients from the harmful effects of X-ray dye used during commonly performed angiographic imaging procedures in the United States and internationally. It offers AVERT, AVERT Plus, DyeVert Plus System, and DyeVert System, which reduces and monitors the contrast dye used in commonly performed heart, cardiovascular, and peripheral procedures. The company was founded in 2005 and is headquartered in Minnetonka, Minnesota.

Details
Name: Osprey Medical, Inc.
OSP
Exchange: ASX
Founded: 2005
A$64,769,605
431,797,370
Website: http://www.ospreymed.com
Address: Osprey Medical, Inc.
5600 Rowland Road,
Suite 250,
Minnetonka,
Minnesota, 55343,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX OSP NPV (CHESS DEPOSITARY INTERESTS) Australian Securities Exchange AU AUD 02. May 2012
Number of employees
Current staff
Staff numbers
0
Osprey Medical employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 10:34
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/02/25
Last earnings filing: 2019/03/25
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.